Japan's Mitsubishi Tanabe is moving forward with a flu vaccine that is produced by implanting genetic material from the flu virus into tobacco leaves, which then produce flulike particles containing antigens to provoke an immune response. The key benefit of the tobacco manufacturing process is that it requires only one month to produce a vaccine, compared to the 6 months required to produce a traditional egg-based jab. The company hopes to get the vaccine to market by 2018 or 2019. More from FierceVaccines